Avidity Biosciences Inc’s filing revealed that its President and CEO Boyce Sarah unloaded Company’s shares for reported $0.77 million on Jun 04 ’24. In the deal valued at $27.42 per share,28,000 shares were sold. As a result of this transaction, Boyce Sarah now holds 112,117 shares worth roughly $2.98 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, LEVIN ARTHUR A sold 5,000 shares, generating $149,481 in total proceeds. Upon selling the shares at $29.90, the Director now owns 14,830 shares.
Before that, MacLean Michael F sold 75,000 shares. Avidity Biosciences Inc shares valued at $2,121,045 were divested by the Chief Financial Officer at a price of $28.28 per share. As a result of the transaction, MacLean Michael F now holds 44,093 shares, worth roughly $1.17 million.
BofA Securities initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on May 03, 2024; the price target was $40. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Evercore ISI also remained covering RNA and has increased its forecast on May 22, 2023 with a “an Outperform” recommendation from previously “an In-line” rating. Evercore ISI revised its rating on March 31, 2023. It rated RNA as “an In-line” which previously was an “an Outperform”.
Price Performance Review of RNA
On Friday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 2.15% to $26.60. Over the last five days, the stock has lost -0.97%. Avidity Biosciences Inc shares have risen nearly 193.92% since the year began. Nevertheless, the stocks have risen 124.28% over the past one year. While a 52-week high of $30.84 was reached on 05/22/24, a 52-week low of $4.82 was recorded on 01/02/24. SMA at 50 days reached $26.09, while 200 days put it at $14.25. A total of 0.92 million shares were traded, compared to the trading of 0.74 million shares in the previous session.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 25.54, which if violated will result in even more drops to 24.48. On the upside, there is a resistance level at 27.42. A further resistance level may holdings at 28.24. The Relative Strength Index (RSI) on the 14-day chart is 48.62, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.66, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.85%. Stochastics %K at 31.62% indicates the stock is a holding.
The most recent change occurred on July 20, 2022 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
